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Abstract
The decision to use 10% neutral buffered formalin ﬁxed, parafﬁn embedded (FFPE) archival
pathology material may be dictated by the cancer research question or analytical technique,
or may be governed by national ethical, legal and social implications (ELSI), biobank, and
sample availability and access policy. Biobanked samples of common tumors are likely to be
available, but not all samples will be annotated with treatment and outcomes data and this
may limit their application. Tumors that are rare or very small exist mostly in FFPE pathol-
ogy archives. Pathology departments worldwide contain millions of FFPE archival samples,
but there are challenges to availability. Pathology departments lack resources for retrieving
materials for research or for having pathologists select precise areas in parafﬁn blocks, a
critical quality control step. When samples must be sourced from several pathology depart-
ments, different ﬁxation and tissue processing approaches create variability in quality.
Researchers must decide what sample quality and quality tolerance ﬁt their speciﬁc purpose
and whether sample enrichment is required. Recent publications report variable success with
techniques modiﬁed to examine all common species of molecular targets in FFPE samples.
Rigorous quality management may be particularly important in sample preparation for next
generation sequencing and for optimizing the quality of extracted proteins for proteomics
studies. Unpredictable failures, including unpublished ones, likely are related to pre-
analytical factors, unstable molecular targets, biological and clinical sampling factors asso-
ciated with speciﬁc tissue types or suboptimal quality management of pathology archives.
Reproducible results depend on adherence to pre-analytical phase standards for molecular
in vitro diagnostic analyses for DNA, RNA and in particular, extracted proteins. With
continuing adaptations of techniques for application to FFPE, the potential to acquire much
larger numbers of FFPE samples and the greater convenience of using FFPE in assays for
precision medicine, the choice of material in the future will become increasingly biased
toward FFPE samples from pathology archives. Recognition that FFPE samples may harbor
greater variation in quality than frozen samples for several reasons, including variations in
ﬁxation and tissue processing, requires that FFPE results be validated provided a cohort of
frozen tissue samples is available.
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When fresh human tissue is obtained by biopsy or
surgery for pathological examination and diagnosis,
it typically is ﬁxed in 10% neutral buffered formalin
or alternative ﬁxative, processed through graded
alcohols and embedded in parafﬁn blocks, i.e., for-
malin ﬁxed, parafﬁn embedded (FFPE) blocks. In
most instances a single or small number of 5 µm
sections is cut from the face of the block and stained
for microscopic analysis. Only a limited number of
deﬁned clinical situations, e.g., intraoperative consul-
tations, renal and muscle biopsies, require tissue
samples to be preserved by other methods e.g., fro-
zen, for diagnostic evaluation. Diagnostic material
including slides and remaining FFPE blocks is
retained in the pathology department and this collec-
tion often is known as the pathology archive. The
suitability of this archive to support the combination
of morphological and immunohistochemical analy-
sis, which remain the cornerstones of clinical
pathology diagnosis, have consolidated the role of
the FFPE preservation format for clinical use.
The collection, processing and storage of human
biospecimens such as blood, body ﬂuids and tissue
with associated patient data for either clinical or
research purposes constitutes what is commonly
known as biobanking (Liu and Pollard 2015),
although a wider deﬁnition encompasses sample col-
lections of all biological types and sources (Hewitt
and Watson 2013, Kinkorová 2016). Human tissue
sample biobanking has medical, ethical, research,
legal, political, commercial and economic ramiﬁca-
tions (Mee et al. 2013, Bjugn et al. 2015) in addition
to its role in facilitating diagnosis and precision med-
icine, i.e., treating each patient according to his or her
personal and genetic characteristics (Liu and Pollard
2015) as well as translational health research. By
contrast to the standard clinical process, when
patients provide informed consent for research bio-
banking, fresh tissue that is surplus to diagnosis is
most often preserved by freezing, e.g., placed in an
ultralow temperature or a vapor phase of liquid
nitrogen freezer. This approach is taken to preserve
cells and subcellular components including nucleic
acids and proteins optimally for use in research pro-
jects. Although preservation as frozen tissue and
frozen blocks has long been regarded as the gold
standard for preservation of tissues for research,
FFPE samples from pathology archives now are
widely used for research.
We review and examine here the factors that
may govern the research decision to use clinical
FFPE tissue, the main product associated with the
clinical pathology department archive, for basic
and translational cancer research.
General factors
When researchers pursue a deﬁned project and
question, they require appropriate samples and linked
data. This material may be available in the existing
“retrospective collections” held in pathology archives
or in biobanks. Alternatively the project may require
the creation of a “bespoke or prospective collection” if
the required samples have not been biobanked
previously or if an unavailable speciﬁc collection and
data protocol are needed. Researchers interested in
rare diseases or in obtaining samples of tumors not
usually resected surgically, such as small cell lung
carcinoma, face signiﬁcant challenges with obtaining
samples collected speciﬁcally for research by either
retrospective or prospective protocols, and a limited
amount of clinical diagnostic FFPE tissue is all that is
likely to be available. Even common tumor types can
become scarce, because of changes in clinical
requirements for diagnosis that have occurred over
time, e.g., lung adenocarcinoma.
Prospective and retrospective
collections
Bespoke prospective collections have been regarded
as higher quality and more efﬁcient than retrospec-
tive biobanked collections, because of the initially
deﬁned purpose that initiated the collection. The
need for a prospective collection, however, usually
delays the progress of the research and such collec-
tions undoubtedly account for many unused old
samples that are held in freezers around the world;
only part of the sample collection may have been
used initially, or grant funding may have been ter-
minated with no mechanism in place for others to
access or identify the samples. By contrast, biobanks
that collect and store samples to maintain a retro-
spective collection usually can provide sufﬁcient
cases to facilitate multiple studies using different
criteria and without delay. Unfortunately, many bio-
banks fail to develop targets for their collections
(Meredith et al. 2015) and, by deﬁnition, these collec-
tions contain many samples that do not meet speciﬁc
study criteria, are never selected and therefore
become unused samples also. As a result, biobanks
of frozen samples exist on all continents and the
problem is compounded by the fact that many are
no longer identiﬁable or ﬁndable and may be of
dubious quality. Despite the large number of high
quality samples in reputable biobanks, a much
greater potential source of material for research is
the pathology archive.
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FFPE and ELSI
Whereas the universal standard is to obtain
patient consent for collection and use of
biobanked samples (usually frozen samples)
for research, FFPE tissue is derived primarily
from pathology archives and the standards for
its subsequent use for research vary among
regions. In Ireland and Canada, consent
requires approaching the patient for consent or
obtaining a waiver of consent from an ethics
review committee as well as approval by
a pathologist or hospital committee. An
example of the type of research where a waiver
is the appropriate and only feasible mechanism
to allow the research to progress is the type of
study where long term patient outcome data is
required to deﬁne the starting patient cohort,
then the corresponding samples from initial
diagnosis and subsequent relapse events can
be obtained only from clinical FFPE materials
(West et al. 2011). Another example is where
unusual or rare samples are needed and
sufﬁcient numbers of cases are likely to be
obtainable only from several pathology archives
and diagnoses spanning many years.
Unfortunately, ethical, legal and social
frameworks regarding access to clinical FFPE
tissue samples are not consistent among
countries (Kaye et al. 2016). Greater awareness
by an educated and informed public of
biobanking and research that depends on
biobanks is needed to support the improvement
of mechanisms that facilitate the use of human
tissues in research (Gaskell and Gottweis 2011).
Opt out consent
Opt out consent (https://www.federa.org/sites/
default/ﬁles/digital_version_ﬁrst_part_code_of_
conduct_in_uk_2011_12092012.pdf) has existed in
Belgium and The Netherlands for many years,
and is allowed in a new European Commission
directive on protection of personal data (https://
ec.europa.eu/info/strategy/justice-and-
fundamental-rights/data-protection_en) and in a




out system is pragmatic and reduces biobanks’
operational costs (Riegman and van Veen 2011).
Individual patients rather than an IRB or medical
ethics committee make the decision regarding use
of residual FFPE tissue, but opt out requires speciﬁc
ethical, legal, institutional and informed societal sup-
port. Detailed discussion of the opt out system is
beyond the scope of this review but is clearly war-
ranted in view of the increased use of FFPE in cancer
research.
Sustainability and costs
Although research biobanks and pathology
archives play complementary roles in supporting
research, the sustainability of these types of
collections is quite different. Maintaining a
biobank that stores frozen samples is expensive
and funding frequently is derived from several
sources including the hospital, university, grants
and industry (Barnes et al. 2014, Henderson et al.
2013). A biobank’s budget is vulnerable, which
requires periodic re-evaluation of its goals,
inventory and sample collection policies to
achieve sustainability (Vaught et al. 2011, Parry-
Jones 2014, Albert et al. 2014). A major biobank
cost that is greater than that for equipment, con-
sumables or data management systems is person-
nel costs, including personnel required for
obtaining informed consent.
Pathology departments have a more depend-
able healthcare budget and are obliged to process
and store tissue, and to issue reports on all col-
lected specimens without exception. Patient spe-
cimens are received in large batches and are
examined systematically and sequentially by a
pathologist, then processed. The FFPE blocks
created are durable and less costly to store than
frozen tissue. Pathology and inventory data also
are maintained as part of the clinical patient
chart, though often not in a format conducive to
efﬁcient search and retrieval using research
criteria as in a biobank.
Special biobank requirements and
integration with pathology
Biobanked frozen samples are more hazardous
than FFPE samples, and have special shipping
requirements (Grizzle et al. 2010). Freezers require
alarm monitors and CO2 back-up systems or liquid
nitrogen replenishment, and make inefﬁcient use
of expensive laboratory space. Integration of the
research biobank with the pathology department
can lead to mutual beneﬁts by sharing facilities,
costs, power and space (Grizzle et al. 1998,
Lawler et al. 2016). Pathology archival samples
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for approved projects may be stored in a biobank
and retrieved efﬁciently for research, provided
there is adequate sample tracking and an urgent
response to clinical care requirements. Importantly,
pathology and biobank staff must work closely
together and understand their respective rules of
engagement.
FFPE blocks
Major challenges to the use of archival FFPE blocks for
cancer research are the ELSI, referred to above, and
that FFPE blocks are generated from procedural
specimens submitted to pathology without quality
control (see “sample processing and standards”
below). Certain pathologists may be unwilling to
share for research tissue that they (wrongly) perceive
to be theirs. Surgical specimens or biopsies,mislabeled
in the operating theaters or clinics (Makary et al. 2007)
or inpathology, andmislabeledblocks or slides clearly
have the potential to jeopardize clinical care or
invalidate research ﬁndings, but such errors are
typically resolved safely by detailed investigation
and careful clinical correlation (Tozbikian et al. 2017);
they are greatly reduced bywell-structured laboratory
protocols, barcoding and sample tracking.
Ownership
In most jurisdictions, pathologists are considered
custodians, but not owners, of patients’ diagnostic
FFPE tissue. US courts, however, have ruled that
tissues are under the control of the healthcare facil-
ity. There have been attempts to deﬁne two
mutually exclusive categories of excised human
tissues, “diagnostic” and “research,” for attributing
ownership of the former to institutions and deﬁn-
ing rules that govern their use in research (Cheung
et al. 2013). This proposal has been debated in
Canada and rejected by the large majority of clin-
icians and researchers - see Cheung et al (2013)
letters in response http://www.cmaj.ca/content/
185/2/135/tab-e-letters
Access to FFPE and cost recovery
Researchers may apply for use of FFPE samples
in the archives for research projects approved by
an ethics review committee, which may or may
not waive the requirement for patient consent.
Although there is a perception that pathologists
present a barrier to researcher access to tissues,
the challenge is that pathology departments are
not structured or resourced to identify and
undertake efﬁciently the work to retrieve sam-
ples for research. Even if the research criteria
for selection of samples are simple or speciﬁc
sample identiﬁers are already known, prior to
the technical staff locating blocks and slides,
which may be stored off-site and under a service
contract, and cutting new sections for the
researchers, a pathologist must review each
patient’s report and pathology slides and blocks
to determine suitability of individual blocks. This
is necessary for several reasons. First, on behalf
of the patient, depleting material that might be
essential for subsequent clinical review for
patient care must be prevented. Second, blocks
are intended to support delineation of multiple
diagnostic features. For tumor specimens these
features include the status of resection margins
and presence of pathology accompanying the tar-
get lesion; even blocks that represent the target
lesion vary signiﬁcantly in their composition
such as the percentage of viable tumor cells.
Also the optimal block identiﬁed in the original
pathology report might be greatly depleted
owing to additional sectioning for immunohisto-
chemical stains carried out at the time of diag-
nosis or previously committed to another
research project. Thus, the pathologist can be
required both for quality control of samples
released for research and for maintaining ade-
quate diagnostic tissue in the pathology depart-
ment to have new slides stained from some
blocks. For the research biobank, these decisions
and most of this work has already been per-
formed at the time of harvesting and allocation
of samples to the biobank and any charges or
costs have been integrated into the operational
model. Furthermore the research biobank also
usually assumes more expenses up front, includ-
ing consent and procedural expenses. By con-
trast, the FFPE archival block is collected and
stored under the clinical procedure consent and
the cost of original FFPE processing and storage
is absorbed by the hospital. Cost recovery
charges, therefore, are clearly justiﬁable (Vaught
et al. 2011, Parry-Jones 2014, Albert et al. 2014),
although understandably the above subtleties are
not always appreciated fully by all researchers.
Sample processing and quality control
Biospecimen science is the systematic study of
the factors that affect sample quality and down-
stream analysis of frozen and ﬁxed samples
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(Moore et al. 2012, Engel et al. 2014). Where
known and applicable, details should be reported
to facilitate reproducibility of the study (Moore
et al. 2012). Although often ignored by research-
ers accessing pathology archives, pre-analytical
variables, reviewed by Bass et al. (2014), affect
both FFPE archival and frozen biobank samples
and include patient factors such as co-morbidities
and stress, warm ischemia during surgery, peri-
operative events, operative changes, cold ische-
mia and the microenvironment from which the
sample was removed. Certain pre-analytical vari-
ables can be recorded, e.g., ambient temperature,
transport time and time from arrival to freezing/
ﬁxation; however, many pre-analytical factors are
unknown, partly understood or patient-speciﬁc.
Some variables are speciﬁc to frozen biobank
samples, including freeze-thaw cycles and degra-
dation of labile components, such as RNA, that
can occur during storage. Other variables are
speciﬁc to FFPE archival specimens, such as the
use of inadequately buffered formalin or ﬁxatives
other than formalin, specimen size, inadequate
formalin perfusion of the specimen, duration of
ﬁxation, delayed pathological examination and a
delay from dissection to processing (van
Maldegem et al. 2008, Zhou et al. 2015). Tissue
processing variables include the use of xylene
substitutes, differences in the time or chemistries
of speciﬁc tissue processor steps (Grizzle WE,
personal communication) and the establishment
of a hydrophobic environment on transfer of the
tissue to xylene (Otali et al. 2009). Additional
variables include the duration of FFPE block sto-
rage (Combs et al. 2016) and exposure of FFPE
blocks to hazards such as rodents and mold.
Immunohistochemistry
Fifty years ago, fresh frozen tissue was considered
essential for preserving antigenicity for immunohis-
tochemical staining (Nakane and Pierce 1966).
Within the ensuing 10 years, however, modiﬁcations
of the immunoperoxidasemethod (Taylor and Burns
1974, Huang et al. 1976, Kurzon and Sternberger
1978), with or without the use of antigen retrieval
techniques (Denk et al. 1977, Cuevas et al. 1994, Shi
et al. 1991, 2011) render FFPE tissue eminently sui-
table for detecting a wide variety of intracellular and
surface antigens by immunohistochemistry for diag-
nostic pathology practice, basic and translational
research and validation of biomarkers. Tissue stabi-
lization reagents such as PAXGENE and BHP are
reported to enhance antigenicity (Kap et al. 2011,
Mueller et al. 2011). The quality of FFPE samples
for immunostaining can deteriorate gradually, how-
ever, with long-term storage for certain antigens
other than actin and keratin (Combs et al. 2016,
Grillo et al. 2015). Indeed, unstained FFPE sections
can begin to lose antigenicity within several weeks
(Jacobs et al. 1996), possibly due to exposure of
molecules in thin sections to the atmosphere.
Quality assurance and quality control
FFPE archival samples can be important for
quality assurance of frozen biobanked samples
and vice versa. Composition can be determined
fairly well by frozen section analysis (Mee et al.
2013), but reference to an adjacent FFPE block
often is better. Comparison of assay perfor-
mance and research results from studies using
frozen tissue with those using an adjacent FFPE
block can help conﬁrm the performance of anti-
bodies (Mee et al. 2011, Greytak et al. 2015) by
extracting protein for western blots. Quality
control is not limited to evaluating the quantity
and quality of extracted DNA and RNA and a
pathologist’s examination, but may require
macrodissection or laser capture microdissection
(Emmert-Buck et al. 1996, Baldelli et al. 2015,
Varley et al. 2014) to enrich the sample for
tumor cells. There is a spectrum from unsatis-
factory to acceptable and insufﬁcient attention
to quality control greatly contributes to the
lack of reproducibility of scientiﬁc research ﬁnd-
ings (Begley and Ioannidis 2015, Grizzle et al.
2015).
Research question, molecular target
and technique to be used
The suitability of FFPE tissue for research
depends on the research question that is asked,
the molecular target and the technique that is
considered for use. Samples that are “imperfect”
for certain research projects may be appropriate
for others. A detailed strategy to quantify and
stratify sample quality appropriate for speciﬁc
research techniques has been proposed by the
ISBER biospecimen science working group
(Betsou et al. 2016). The technique to be used
requires knowledgeable, adaptable and expert
technical staff in addition to appropriate labora-
tory instrumentation. Commonly, FFPE tissue
requires especially rigorous pre-analytical phase
preparation prior to using a technique originally
designed for frozen tissue (see below). Antigen
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retrieval by heat pretreatment of FFPE sections is
part of diagnostic pathology practice for immuno-
histochemical staining and assays etc. (Shi et al.
2011). Not all results from translational research
laboratories can be “readily reproduced,” how-
ever, because tissue preparation methods are too
variable or because of the involvement of other
factors such as poor quality assurance or sample
selection bias (Yeo et al. 2014, Neumeister et al.
2014, Atherton et al. 2016).
Biological studies associated with multi-site
clinical projects and trials that seek to establish
the role of new biomarkers and associated targeted
therapies usually rely on retrieval of existing FFPE
archival tissue samples, derived from multiple
pathology departments (Sparano et al. 2015).
Formalin ﬁxation and tissue processing (Otali
et al. 2009, Atherton et al. 2016), however, are not
uniform in all specimen types, particularly in older
resection specimens or from institution to institu-
tion. Therefore, critical decisions for advances in
patient treatment might be based on examination
of FFPE sections that may not be comparable.
Therefore, it would be highly desirable, for both
consistency and clinical care, to establish objective
and reliable tissue quality controls for FFPE sec-
tions (Yeo et al. 2014, Neumeister et al. 2014).
Analysis of chromosomes, DNA, RNA,
MicroRNA, and proteins in FFPE tissue
FFPE samples may be all that is available to a
researcher or may be the optimal sample for pur-
suing a speciﬁc research question. What are its
limitations in selected molecular investigations?
Chromosomes
Many molecular techniques for assessing aspects
of DNA have been modiﬁed successfully for
application to FFPE tissue (Dietel 2016). FFPE
tissue can be used to detect chromosomal aberra-
tions using microarray comparative genomic
hybridization (Toffoli et al. 2014, Pinto et al.
2016). FFPE tissue also can be used to probe
speciﬁc genetic sequences and structural or
numerical chromosomal aberrations by ﬂuores-
cence in situ hybridization (FISH) (Lim and Lim
2017). FISH assays have signiﬁcant clinical diag-
nostic utility for soft tissue tumors (Horn et al.
2014) and are employed routinely on FFPE sec-
tions of breast cancer tissue to determine
whether a patient has multiple copies of the
HER2 gene, which predicts that trastuzumab
(Herceptin) therapy would be beneﬁcial (Griggs
et al. 2017, Morey et al. 2016).
DNA
Although there is better quality DNA in fresh or
frozen tissue, it has long been known that DNA
can be extracted for gel-based analysis from FFPE
tissue (Watson et al. 1993) and improved extraction
methods continue to be reported (Potluri et al.
2015). Nevertheless, DNA extracted from FFPE
cancer tissue harbors potential sequence artifacts
(Do and Dobravic 2015) and is associated with
higher false-negative and false-positive rates of
mutation than frozen tissue (Gallegos Ruiz et al.
2007). This is because formalin ﬁxation forms
cross-links, causes DNA degradation and intro-
duces chemical contaminants that may affect
experimental reagents. Errors in mutation detec-
tion associated with low numbers of functional
DNA copies and DNA de-amination artifacts
account for most false positives, although newer
methodologies may be able to reduce these errors
signiﬁcantly (Bourgon et al. 2014).
Next generation sequencing (NGS)
Quality management and awareness of limitations
of FFPE are vitally important (Bourgon et al. 2014,
Grizzle et al. 2015, de Abreu et al. 2016). Rigorous
quality management and FFPE tissue pre-
preparation, including optimized library prepara-
tion, are required for clinical application of NGS
(de Abreu et al. 2016, Bolognesi et al. 2016) applied
to FFPE DNA to detect reproducibly copy number
variations and single nucleotide variations (Shao
et al. 2016). These investigators reported 100% con-
cordance of mutation proﬁles between discovery
and validation cohorts when comparing an opti-
mized NGS approach to conventional assays,
including PCR, FISH and IHC, applied to clinical
lung adenocarcinoma samples. Bolognesi et al.
(2016) employed a microchip-based digital sorter
to obtain pure cell populations for NGS from FFPE
tissue. Astolﬁ et al. (2015) reported that if DNA in
FFPE was of high quality, results of whole exomic
sequencing were equivalent to those obtained from
frozen tissue samples. Others have reported
equivalent frozen and FFPE tissue data based on
a small series of cases (Munchel et al. 2015,
Bonﬁglio et al. 2016). Whole exomic sequencing
data from FFPE gDNA extracted from samples of
gastrointestinal stromal tumors and melanomas,
however, were not consistently comparable to fro-
zen tissue results; this was attributed to the fact
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that certain clinical samples yield lower quality
DNA and might be the only samples available for
important clinical decision making (Astolﬁ et al.
2015, De Paoli-Iseppi et al. 2016). Bioinformatics
analysis, essential for interpretation of NGS data,
must be adapted to FFPE-based data.
Standardization (see below) is essential for transla-
tional and clinical applications.
RNA
RNA can be extracted from FFPE tissue, but it is
degraded into smaller fragments than in frozen
tissue (Micke et al. 2006, Sun et al. 2016).
Kashofer et al. (2013) examined the impact of pre-
analytical factors and quality control measures
required to improve the reliability of RNA extrac-
tion from FFPE. Small amounts of input RNA can
be detected and quantiﬁed by reverse transcription
quantitative real-time polymerase chain reaction
(RT-qPCR) (Dama et al. 2016), which is more sen-
sitive than FISH or immunohistochemistry (Lung
et al. 2016). Paluch et al. (2017) reported that a
targeted RNA sequencing panel proﬁled mRNA
expression levels reliably in FFPE samples of ovar-
ian carcinoma and was concordant with results
from matching mRNA expression from freshly fro-
zen samples and determined by RT-PCR. Cieslik
et al. (2015) reported improved results from RNA
sequencing of degraded RNA using an exome-
capture transcriptome protocol. An mRNA-based
in situ mutation detection technique based on pad-
lock probes showed differences in mutant allele
frequencies within two morphologically homoge-
neous colorectal cancers (El-Heliebi et al. 2017).
Morten et al. (2016) reported variable success in
detecting a p53 mRNA isoform (delta40p53) using
two different assays applied to matched frozen and
FFPE tissue samples. The apparently capricious
detection of mRNA in FFPE tissue might be due
to differences between individual mRNA mole-
cules, the variable impact of known pre-analytical
variables or suboptimal quality management.
MicroRNA (mi-RNA)
Mi-RNAs are easier to retrieve from FFPE than
mRNA owing to their small size and relative sta-
bility (Howe 2017). Based on analysis of pathol-
ogy archival samples, biomarkers based on mi-
RNA features determined from FFPE tissues are
therefore potentially very useful for developing
precision medical strategies (Caramés et al. 2016,
Wong et al. 2016); however, mi-RNA in FFPE
material may not be immune to pre-analytical
variables. The global mean yield of mi-RNA is
lower with increased ﬁxation time and in older
parafﬁn blocks (Boisen et al. 2015). Furthermore,
How et al. (2015) reported that a prognostic 9-mi-
RNA signature set for cervical carcinoma identi-
ﬁed in frozen samples could not be validated in
an independent cohort of FFPE samples and that
concordance between frozen and FFPE samples
was lacking. A 2-miRNA classiﬁer (miR-21 +
miR-155), validated in small cohorts of EUS-FNA
and FFPE needle biopsies, exhibited 81.5% sensi-
tivity and 85.7% speciﬁcity in distinguishing pan-
creatic cancer from benign pancreatic lesions
(Frampton et al. 2016). Kakimoto et al. (2016)
reported that mi-RNA stability in FFPE tissue
correlated with guanine and cytosine (GC) con-
tent: GC-rich mi-RNAs were less degraded than
those with < 40% GC content. Therefore, intratu-
mor and interpatient heterogeneity of mi-RNA
expression in FFPE tissue (Jepsen et al. 2016)
should not be unexpected.
Proteins
FFPE tissue-based proteomics is an alternative
approach to discovery and evaluation of biomarkers
for precision medicine. Proteins are much less amen-
able to extraction from FFPE, however, than from
frozen tissue (Thompson et al. 2013, Shi et al. 2013,
Steiner et al. 2014). More importantly, by contrast to
the often more forgiving assays of DNA and RNA,
the quality of extracted protein is an important fac-
tor. Individual phosphorylated proteins may show
increased, decreased, or stable immunohistochem-
ical expression with increasing delays before forma-
lin ﬁxation (Vassilakopoulou et al. 2015, Atherton
et al. 2016, Grizzle et al. 2016). Reverse phase protein
arrays (RPPA) immobilize and proﬁle the entire pro-
tein repertoire of the sample (Paweletz et al. 2001).
RPPAwas used for the Cancer GenomeAtlas project
(Weinstein et al. 2013) and has enhanced utilitywhen
integrated with other analytical platforms (Lu et al.
2016). Mass spectrometry-based quantitative proteo-
mics traditionally has been performed on fresh or
frozen tissue but its application to FFPE is expensive
and challenging (Steiner et al. 2014, Lu et al. 2016).
Perhaps the most critical issue for proteomics
studies is the quantitative recovery of proteins
from the FFPE sample prior to downstream analy-
sis (Shi et al. 2013). Ethanol and xylene-free depar-
afﬁnization using hot distilled water only provides
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an increased yield of proteins extracted from archi-
val parafﬁn blocks (Mansour et al. 2014). Heat-
induced antigen retrieval (Shi et al. 2006), based
on antigen retrieval for immunohistochemistry
(Shi et al. 1991), and elevated hydrostatic pressure
(Fowler et al. 2008) also have been reported to
increase the yield of proteins extracted from FFPE
tissue. Recent progress with optimization of pro-
teomics platforms has enabled the threshold for
analysis to be lowered to single 10 µm sections
(Hughes et al. 2016).
Kojima et al. (2012) reported a robust method
for protein extraction using heat-induced anti-
gen retrieval and trypsin digestion, with valida-
tion in small cohorts of FFPE human pancreatic
cancer and matched FFPE and frozen mouse
pancreatic tissue samples. Complete solubiliza-
tion of FFPE tissue sections has been proposed
as part of the protein extraction procedure, but
there is no consensus concerning the optimal
protocol for protein extraction from FFPE tis-
sues (Shi et al. 2013). Moreover, there are many
types of mass spectrometry instrumentation that
may produce divergent results from aliquots of
the same FFPE sample. A result is not necessa-
rily representative of the speciﬁc cell type under
investigation in frozen or FFPE tissue and fail-
ure to identify a protein does not indicate its
absence, because there are no practicable nor-
malization approaches (analogous to housekeep-
ing genes) for analyzing proteins. Despite these
signiﬁcant challenges, analysis of proteins by
mass spectrometry can be a useful discovery
tool if results are conﬁrmed by other techniques.
Standards
The European Committee for Standardization has
produced pre-analytical phase standards for protein,
DNA and RNA extraction from FFPE
https://standards.cen.eu/dyn/www/f?p=
2 0 4 : 1 1 0 : 0 : : : : F S P _ P RO J E C T : 4 1 0 4 6& c s =
1FD7275F5AE4E23C9D30AF3C7F4824F6E,
https://standards.cen.eu/dyn/www/f?p=
2 0 4 : 1 1 0 : 0 : : : : F S P _ P RO J E C T : 4 1 0 4 4& c s =
118071B8B9C4BA81C9C3680A98DEC61D8,
https://standards.cen.eu/dyn/www/f?p=
2 0 4 : 1 1 0 : 0 : : : : F S P _ L A N G _ I D , F S P _
P R O J E C T : 2 5 , 4 1 0 4 2 & c s =
1988037AFFA089882B7D6CD54AB81B5F2.
These documents are intended to standardize the
pre-analytical process of sample collection and
will soon be published as ISO international stan-
dards. Where standardization is not possible, doc-
umentation helps identify the many potential
variables that may compromise a sample. The
documentation of sample metadata is the key
tool for identifying sources of variation that can
lead to incorrect measurements. Identifying a
source of variation may direct the exclusion of a
sample from a particular cohort or form the basis
for reassessment of the adherence to pre-analytical
protocols before collecting additional samples.
General adoption of the pre-analytical standards
will create more possibilities for the use of FFPE
samples for medical research with greater exchan-
geability of equivalent samples that will enable
multicenter studies to become more successful.
The development of each set of new therapies
and diagnostic tests is followed by continuous
improvements in tools, assays and methods, and
success depends on reproducibility after valida-
tion for the intended uses. Validation is obligatory
before a new method can be accepted for health
care (Burke and Grizzle in press). The latter also is
an argument for choosing or adapting approaches
to be able to analyze FFPE materials early in the
progress of a cancer research study.
Conclusion
The decision to use FFPE pathology archival mate-
rial for cancer research may be dictated by the
research question and analytical technique.
Alternatively, the decision may be a compromise
or no choice at all depending on the country,
national ELSI, sample and biobank availability,
and access policy. Biobanked frozen samples of
common cancers are likely to be available, but
determinants such as associated treatments and
availability of outcomes data may limit their appli-
cation. Microscopic lesions and rare tumors will, for
all practical purposes, exist mostly in FFPE pathol-
ogy archival samples and may need to be obtained
from several pathology departments to accumulate
adequate numbers; however, care should be exer-
cised to avoid biases that may be caused by site
differences including different ﬁxation and tissue
processing approaches (Atherton et al. 2016, Burke
and Grizzle in press). Investigators must decide the
sample quality that is ﬁt to answer a speciﬁc
research question. Recent publications report vari-
able successes with techniques modiﬁed to examine
all common molecular targets in FFPE samples.
Unpredictable failures likely are related to pre-
analytical factors, unstable molecular targets or
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biological and clinical sampling factors associated
with speciﬁc tissue types. More reproducible
results should follow adherence to pre-analytical
phase standards for molecular diagnostic analyses
in vitro for DNA, RNA, and in particular, extracted
proteins. Experienced personnel and appropriate
equipment are essential. With continuing adapta-
tions of techniques for application to FFPE, the
greater potential to acquire larger numbers of
FFPE samples, and the greater convenience of
using FFPE in assays for precision medicine, the
choice of material in the future will be increasingly
biased toward FFPE samples from pathology
archives (Hughes et al. 2010). The realization that
FFPE may be of poorer quality, because more var-
iations are introduced by ﬁxation and tissue proces-
sing to parafﬁn than in freezing tissue, however,
would require that FFPE results be veriﬁed using a
cohort of frozen tissue samples for complete under-
standing of the disease process.
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